Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.
| Current Price | ₹1,704.40 |
|---|---|
| Market Cap | ₹32,314 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 34.9 |
| Return on Equity | 19.57% |
| 52-Week Range | ₹1,228.90 – ₹1,830.00 |
| Beta (1Y) | 0.11 |
| Dividend Yield | 0.21% |
1. Pharmaceuticals-100%
Emcure Pharmaceuticals Ltd is trading at ₹1,704.40, with a market capitalisation of ₹32,314 Cr.
Emcure Pharmaceuticals Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space.
Emcure Pharmaceuticals Ltd has a P/E of 34.9 and a return on equity of 19.57%.